Bipolar depression: diagnostic and treatment considerations.
Bipolar affective disorder is a recurrent, disabling, and potentially lethal illness that typically begins early in life. Although the disorder is defined by the manic and hypomanic episodes, for most people the depression episodes are the more virulent aspect of the illness. Specifically, the depressive episodes are more numerous, last longer, and are more difficult to treat than the manias, and depression is the principal cause of the illness's increased mortality due to suicide. For people with early-onset depression, predictors of subsequent bipolarity include a family history, psychotic features, and reverse neurovegetative features. Initial episodes of depression are commonly misdiagnosed, which often delays initiation of appropriate therapy and increases the likelihood of treatment with antidepressants alone. Unfortunately, the correct diagnosis is often not made until there has been a treatment-emergent affective switch. There are no treatments specifically approved for bipolar disorder in youth and, among antidepressants, only fluoxetine has received approved. When bipolarity is suspected, treatment with mood stabilizers, both conventional (i.e., lithium, valproate, and carbamazapine) and more recently classified (lamotrigine) and atypical antipsychotics should be prioritized. When antidepressants are indicated in combination with mood stabilizers, first choice options include bupropion and the selective serotonin reuptake inhibitors. Studies of adults indicate that several forms of focused psychotherapy may improve longer term outcomes.
Thase
Michael E
ME
Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, PA 15123-2593, USA. thaseme@upmc.edu
D017668:Age of Onset; D000928:Antidepressive Agents / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000627:therapeutic use; D001714:Bipolar Disorder / Q000175:diagnosis* / Q000523:psychology / Q000628:therapy*; D002648:Child; D003866:Depressive Disorder / Q000175:diagnosis* / Q000628:therapy*; D003937:Diagnosis, Differential; D018682:GABA Agents / Q000627:therapeutic use; D006801:Humans; D015995:Prevalence; D011613:Psychotherapy; D014635:Valproic Acid / Q000627:therapeutic use
D000928:Antidepressive Agents; D014150:Antipsychotic Agents; D018682:GABA Agents; D014635:Valproic Acid